We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $1.85M
1-Year Est. Return 176.16%
This Fund
S&P 500
This Quarter Est. Return
+11.03%
1 Year Est. Return
+176.16%
3 Year Est. Return
+511.75%
5 Year Est. Return
+854.95%
10 Year Est. Return
+8,566.11%
AUM
$98.2M
AUM Growth
+$34.1M
Cap. Flow
+$27.8M
Cap. Flow %
28.27%
Top 10 Hldgs %
98.04%
Holding
17
New
6
Increased
7
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
KALA icon
KALA BIO
KALA
+$12M
2
GARS
Garrison Capital Inc.
GARS
+$6.47M
3
MTEM
Molecular Templates, Inc.
MTEM
+$5.84M
4
JBGS
JBG SMITH
JBGS
+$1.22M
5
SBBP
Strongbridge Biopharma plc.
SBBP
+$828K

Top Sells

Rank Stock Value
1
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$300K
2
TMH
Team Health Holdings Inc
TMH
+$174

Sector Composition

Rank Sector Weight
1 Healthcare 69.09%
2 Miscellaneous 19.7%
3 Financials 9.55%
4 Real Estate 1.26%
5 Consumer Discretionary 0.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SBBP
1
DELISTED
Strongbridge Biopharma plc.
SBBP
$38.1M 38.73%
5,514,994
+120,000
+2% +$828K
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$818B
$19.4M 19.7%
77,052
+13,869
+22% +$3.42M
KALA icon
3
KALA BIO
KALA
$10.8M
$12.4M 12.65%
+218
New +$12M
AGRX
4
DELISTED
Agile Therapeutics
AGRX
$8.12M 8.26%
910
+98
+12% +$753K
GARS
5
DELISTED
Garrison Capital Inc.
GARS
$7.17M 7.29%
850,000
+781,298
+1,137% +$6.47M
MTEM
6
DELISTED
Molecular Templates, Inc.
MTEM
$7.07M 7.19%
+67,586
New +$5.84M
BRK.B icon
7
Berkshire Hathaway Class B
BRK.B
$1.09T
$1.64M 1.67%
8,945
– –
JBGS
8
JBG SMITH
JBGS
$688M
$1.24M 1.26%
+36,129
New +$1.22M
INDP icon
9
Indaptus Therapeutics
INDP
$155M
$681K 0.69%
+34
New +$490K
ICMB icon
10
Investcorp Credit Management BDC
ICMB
$12.3M
$574K 0.58%
61,859
+6,371
+11% +$63K
ONCT
11
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$531K 0.54%
+449
New +$404K
ADNT icon
12
Adient
ADNT
$1.51B
$398K 0.41%
4,737
– –
TMH
13
DELISTED
Team Health Holdings Inc
TMH
$335K 0.34%
7,709
-4
-0.1% -$174
JAZZ icon
14
Jazz Pharmaceuticals
JAZZ
$16.1B
$306K 0.31%
1,997
+7
+0.4% +$1.06K
ACRS icon
15
Aclaris Therapeutics
ACRS
$876M
$263K 0.27%
10,176
+38
+0.4% +$1.02K
MRNS
16
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$95K 0.1%
+4,050
New +$45.4K
PRTK
17
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-12,456
Closed -$300K

Similar funds

1IC
1922 Investment Company Houston, Texas $1.89M AUM 15.39% 1-Year Est. Return
MP
MVM Partners Boston, Massachusetts $1.91M AUM 81.42% 1-Year Est. Return
HGCK
HPC Germany & Co KG Potsdam, Germany $1.68M AUM 15.3% 1-Year Est. Return
CA
Cohalo Advisory Snoqualmie, Washington $1.65M AUM 11.44% 1-Year Est. Return
CAM
Creekmur Asset Management Morton, Illinois $2.07M AUM
FLC
Fifth Lane Capital Austin, Texas $1.63M AUM 7.3% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $1.56M AUM 25.68% 1-Year Est. Return
DCM
Dupont Capital Management Wilmington, Delaware $2.18M AUM 50.81% 1-Year Est. Return

Caxton Corporation's Q3 2017 Portfolio in Review

As of Q3 2017, Caxton Corporation held 17 positions worth $98.2M, up 53% from $64.1M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Caxton Corporation deployed $27.8M of net new capital in Q3 2017, opening 6 new positions and adding to 7 existing holdings. Its largest new stake was KALA BIO: 218 shares worth $12.4M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 72% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Team Health Holdings Inc, an estimated $174 trimmed.

  • Caxton Corporation's largest Q3 2017 buy was KALA BIO: 218 shares worth $12.4M.
  • Caxton Corporation added most to Garrison Capital Inc. in Q3 2017, an estimated $6.47M increase.
  • Caxton Corporation's biggest Q3 2017 reduction was Team Health Holdings Inc, cutting an estimated $174.
  • Caxton Corporation fully exited Paratek Pharmaceuticals, Inc. in Q3 2017, selling an estimated $300K.
  • Caxton Corporation's ten largest holdings make up 98% of its $98.2M portfolio in Q3 2017.
  • Caxton Corporation opened 6 new positions and closed 1 in Q3 2017.
  • Caxton Corporation's portfolio value rose 53% quarter-over-quarter to $98.2M.

Based on Caxton Corporation's 13F filing for Q3 2017, filed 14 Nov 2017.